Equity Overview
Price & Market Data
Price: $9.77
Daily Change: +$0.23 / 2.35%
Range: $9.42 - $9.77
Market Cap: $487,512,672
Volume: 213,209
Performance Metrics
1 Week: 13.11%
1 Month: 4.84%
3 Months: -6.88%
6 Months: 10.80%
1 Year: 5.75%
YTD: 3.61%
Company Details
Employees: 97
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.